AVTX-803(L-Fucose) Phase III Clinical Trial Has Concluded, And Approval Is Expected in 2027.
Apr 24, 2026
Leave a message
一,Overview(LAD-II / SLC35C1-CDG)
Autosomal recessive rare genetic disease caused by SLC35C1 gene mutation, leading to GDP-fucose transporter deficiency. Core manifestations: recurrent bacterial infections, severe developmental delay, Bombay phenotype; only 30-40 confirmed cases worldwide, more common in consanguineous families in the Middle East and North Africa.
二,Latest progress of AVTX-803 (the only new drug in development under LAD-II)
1. Clinical stage and data (early 2026)
Phase III pivotal trial (NCT05462587) completed enrollment (4 global patients) with oral dose of 1400-1700mg/kg/day. sLeX expression approached normal levels, infection frequency decreased, developmental indicators improved, and Bombay phenotype relieved; 1-year data from long-term extension trial (NCT05754450) showed only mild bloating and diarrhea, no severe liver/kidney damage, and long-term safety was controllable.
2. Regulatory and Listing Outlook
Granted FDA Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation; Phase III completed, NDA expected to be submitted in late 2026-early 2027, and approval is expected in mid-2027 (the world's first standard therapy for LAD-II).
3. Accessibility
Only available to confirmed children in the US through clinical trials/Expanded Access; no compliant access channels in China and other regions, and AVTX-803 has not applied for clinical trials in China.
三,Other key developments
1. Updated diagnostic criteria: Gold standard is decreased/absent sLeX (CD15s) expression on neutrophils + biallelic pathogenic mutations in SLC35C1;
2. Gene therapy (Kresladi) has been approved for LAD-I, no gene therapy in development for LAD-II, and AVTX-803 is the only treatment hope.
Core Specifications and Quality Standards of AVTX-803
The core component of AVTX-803 is high-purity oral L-Fucose. The following specifications are divided into two parts: API (Active Pharmaceutical Ingredient) quality standards and key clinical research indicators, both compiled based on publicly disclosed documents from Avalo Therapeutics and clinical trial data.
| Item | Specification | Remarks |
|---|---|---|
| Active Ingredient | L-(-)-Fucose, CAS 2438-80-4 | Molecular formula: C₆H₁₂O₅; Molecular weight: 164.16 |
| Purity | ≥99.0% (by HPLC) | The clinical formulation adopts high pharmaceutical-grade purity to meet the safety requirements for long-term administration at high doses. |
| Appearance | White crystalline powder | Freely soluble in water; odorless, slightly sweet taste. |
| Water Content | ≤0.5% (by Karl Fischer titration) | To avoid stability degradation under high-humidity conditions. |
| Residue on Ignition | ≤0.1% | To control residual inorganic impurities. |
| Heavy Metals (as Pb) | ≤10 ppm | Complies with USP/EP pharmaceutical-grade standards. |
| Microbial Limits | Total Aerobic Count ≤10³ CFU/g; Mold & Yeast ≤10² CFU/g | General requirements for oral preparations. |
| Key Impurities | No detectable exogenous sugars (glucose, galactose, etc.) or residual organic solvents | To avoid interference with glycosylation processes. |
Our high-purity L-Fucose satisfies all the aforementioned quality specifications, with endotoxin levels strictly controllable to meet pharmaceutical-grade and clinical application standards.

